MarketLens
Sign Up

Amicus Therapeutics: A Rare Disease Gem Acquired

9 months ago
SHARE THIS ON:

Amicus Therapeutics: A Rare Disease Gem Acquired

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•1 week ago

BioMarin Pharmaceutical Hits $1 Billion Revenue Milestone, Advances Rare-Disease Pipeline

BioMarin Pharmaceutical hit $1B in revenue while advancing newly acquired rare-disease drug candidates and integrating Amicus Therapeutics, executives said. The company is also working to reduce debt.
Stock News•2 months ago

PTC Therapeutics: An Acquisition Which Could Unlock Massive Potential

PTC Therapeutics' valuation may not fully reflect upside from Sephience and potential ST-920 approval. Sephience drives 63% of product revenue, while ST-920, a late-stage Fabry gene therapy, could sig...
Stock News•4 months ago

uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix

uniQure is shifting gene therapy focus beyond Hemgenix toward CNS pipeline expansion, with AMT-130 as the centerpiece, supported by faster regulatory pathways and a streamlined business model.

Breaking News

View All →

Top Headlines

View More →
Press Release•34 minutes ago

Advanced Micro Devices, Inc. Investigated on Behalf of Investors with $100,000 or More in Losses - Contact the DJS Law Group to Discuss Your Rights – AMD

Stock News•1 hour ago

Methuselah Advisors Issues Open Letter to the Board of Directors of NVIDIA Corporation

Stock News•1 hour ago

Stock Market Today, Nov. 20: Amazon Shares Slide on AI and Mega-Cap Tech Sell-Off

Stock News•1 hour ago

AMD Investors Have Opportunity to Join Advanced Micro Devices, Inc. Fraud Investigation with SBS Law

Stock News•1 hour ago

Nvidia Plunges as SEC Probe Deepens AI Market Selloff | Closing Bell